Wird geladen...
Tumor-derived interleukin-33 promotes tissue-resident CD8(+) T cells and is required for checkpoint blockade tumor immunotherapy
Immune checkpoint blockade (ICB) immunotherapy has revolutionized cancer treatment by prolonging overall survival of cancer patients. Despite advances in the clinical setting, the immune cellular network in the tumor microenvironment (TME) that mediates such therapy is not well understood. Interleuk...
Gespeichert in:
| Veröffentlicht in: | Cancer Immunol Res |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7642190/ https://ncbi.nlm.nih.gov/pubmed/32917659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-19-1024 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|